The episode provides a year-in-review for AI and a series of predictions for 2026.
The hosts, Elad and Sarah, discuss the rapid adoption of AI in conservative professions, the potential for market volatility around key players like NVIDIA, and the future of robotics, where incumbents like Tesla and Waymo are expected to lead.
They also touch on the underrated impact of GLP-1 drugs in healthcare and the mainstreaming of biohacking.
The episode concludes with a series of rapid-fire predictions from industry experts on topics ranging from AI agents and open-source models to AI drug discovery and energy-efficient computing.
12 quotes
Concerns Raised
Potential for a market downturn if AI companies like NVIDIA fail to meet extremely high expectations.
Systemic risk from the AI CapEx cycle if end-user demand does not materialize.
High market concentration in a few key AI players, creating fragility.
Hype cycles in emerging areas like robotics may lead to a collapse in sentiment if initial deployments are not perfect.
Opportunities Identified
Rapid AI adoption in traditionally slow-moving industries like medicine, law, and accounting.
Breakout consumer AI applications, particularly agent-based software.
Scientific breakthroughs driven by new foundation models in physics, materials science, and biology.
Significant follow-on investment in peptide and hormone therapies spurred by the success of GLP-1s.